Grant Jerome Alan

CEO Grant Jerome Alan sold 60,040 shares of UTI at $34.95 on 2026-02-27 for $2.1M; stock now at $37.40 (+0.0% from 52-week high).

CEO Grant Jerome Alan sold 60,040 shares (60.0K shares) for $2,098,494.06 ($2.1M), reducing his holdings from 490,255 shares to 430,215 shares, a reduction of 12.2% of his pre-transaction holdings. The sale occurred at $34.95 while the current price is $37.40, indicating the stock has appreciated $2.45 per share (7.0%) since the transaction. His cross-ticker track record shows 2 prior sells with an average 90-day return of +7.1%, suggesting his prior sales were generally poorly timed; his same-ticker history at UTI includes 1 well-timed sale (2024-08-23 with 90d +34.6%) and 1 poorly timed sale (2025-05-12 with 90d -20.5%), yielding a 50% well-timed rate at this ticker. The company's fundamentals show annual revenue growth of +14.0% with a P/E of 38.16, indicating a premium valuation despite solid growth.

CEO Jerome Alan sold 56,492 shares (56.5K) at $33.80, reducing holdings to 344,624 shares (14.1% reduction).

CEO Jerome Alan executed a substantial open-market sale of 56,492 shares at $33.80 on 2025-05-12, representing a 14.1% reduction in his post-transaction holdings of 344,624 shares. The sale occurred near the company's 52-week high of $34.33, with the stock currently trading at $33.10 and having gained 20.8% over the prior 30 days and 21.7% over 90 days. His prior sale at this ticker on 2024-08-23 produced a 90-day return of +34.6%, reflecting poorly-timed execution as the stock rose substantially after the transaction (well-timed rate: 0.00% across his prior sales at UTI). Fundamentally, UTI is growing revenues 20.6% annually and trading at a P/E of 31.23, though the CEO's discretionary sale during a multi-month uptrend provides no direct signal about confidence or conviction—it reflects only his personal capital allocation at an elevated price level relative to recent history.

CEO Jerome Alan sells 68,000 UTI shares at $17.53; holdings cut to 136,443 shares (-33.3%)

Chief Executive Officer Jerome Alan sold 68,000 shares (68.0K shares) of Universal Technical Institute at $17.53 on 2024-08-23, reducing his stake by -33.3% to 136,443 shares (136.4K shares) post-transaction. The sale occurred near the company's 52-week high of $19.43, with current price at $17.33 showing -10.8% decline from that peak. UTI is trading at a P/E of 31.51 with annual revenue growth of +45.0% and a market cap of $932.6M, suggesting a high-valuation growth profile. The magnitude of the CEO's stake reduction—eliminating one-third of his holdings in a single transaction—signals a material shift in his personal equity exposure to the company he leads.